Get research updatesPublic study records, presented in a clearer and more patient-friendly format for mental health research discovery.
This study evaluates the safety and effectiveness of Aticaprant for people with depression.
This study ended early.
In FranceA Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia
This study ended early.
In FranceA Randomized, Double-blind, Multicenter, Active-Controlled Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Treatment-resistant Depression
This study has finished and is no longer accepting participants.
In FranceA Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation
This study has finished and is no longer accepting participants.
In FranceCONSTATRE: Risperdal Consta Trial Of Relapse Prevention And Effectiveness
This study has finished and is no longer accepting participants.
In FranceRandomized, Double-blind, Placebo-controlled add-on Trial of the Safety and Efficacy of RO4917838 in Outpatients on Select Atypical Antipsychotics With Prominent Negative or Disorganized Thought Symptoms
This study has finished and is no longer accepting participants.
In FranceA Phase III, Multi-Center, Randomized, 24 Week, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate Efficacy and Safety of RO4917838 in Stable Patients With Persistent, Predominant Negative Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 28 Week, Double-Blind Treatment Period
This study has finished and is no longer accepting participants.
In FranceResearchers compared RO4917838 and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
This study has finished and is no longer accepting participants.
In FranceA Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of ACP-103 in the Treatment of Psychosis in Parkinson's Disease
This study has finished and is no longer accepting participants.
In FranceA Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson's Disease
This study has finished and is no longer accepting participants.
In FranceResearchers studied Paliperidone palmitate 3 month formulation (PP3M) to find out how it affected psychotic symptoms in people with schizophrenia.
This study has finished and is no longer accepting participants.
In FranceA Phase 1, Open-label, Cross-over Study in Healthy Volunteers to Assess the Pharmacokinetic Profile of Prazosin and Cyproheptadine Following Single Dose Oral Administration of KT110 Tablet and Following Administration of Alpress and Periactin Marketed Tablets
This study has finished and is no longer accepting participants.
In FranceWe gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.